|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HSD17B6 |
Gene summary for HSD17B6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HSD17B6 | Gene ID | 8630 |
| Gene name | hydroxysteroid 17-beta dehydrogenase 6 | |
| Gene Alias | HSE | |
| Cytomap | 12q13.3 | |
| Gene Type | protein-coding | GO ID | GO:0006091 | UniProtAcc | A0A024RB43 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8630 | HSD17B6 | NAFLD1 | Human | Liver | NAFLD | 4.59e-04 | 5.08e-01 | -0.04 |
| 8630 | HSD17B6 | S43 | Human | Liver | Cirrhotic | 5.26e-03 | -1.07e-01 | -0.0187 |
| 8630 | HSD17B6 | HCC1_Meng | Human | Liver | HCC | 5.86e-25 | -2.04e-01 | 0.0246 |
| 8630 | HSD17B6 | HCC2_Meng | Human | Liver | HCC | 5.01e-07 | -2.74e-01 | 0.0107 |
| 8630 | HSD17B6 | HCC1 | Human | Liver | HCC | 2.12e-15 | 3.71e+00 | 0.5336 |
| 8630 | HSD17B6 | HCC2 | Human | Liver | HCC | 2.07e-10 | 3.16e+00 | 0.5341 |
| 8630 | HSD17B6 | Pt13.a | Human | Liver | HCC | 5.01e-20 | 5.37e-01 | 0.021 |
| 8630 | HSD17B6 | Pt13.b | Human | Liver | HCC | 3.47e-35 | 4.41e-01 | 0.0251 |
| 8630 | HSD17B6 | Pt14.b | Human | Liver | HCC | 1.04e-08 | 5.66e-01 | 0.018 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00442825 | Liver | NAFLD | small molecule catabolic process | 91/1882 | 376/18723 | 8.96e-16 | 1.31e-12 | 91 |
| GO:19013616 | Liver | NAFLD | organic cyclic compound catabolic process | 105/1882 | 495/18723 | 7.04e-14 | 5.15e-11 | 105 |
| GO:00082023 | Liver | NAFLD | steroid metabolic process | 69/1882 | 319/18723 | 5.90e-10 | 1.28e-07 | 69 |
| GO:00160426 | Liver | NAFLD | lipid catabolic process | 63/1882 | 320/18723 | 1.35e-07 | 1.02e-05 | 63 |
| GO:00060917 | Liver | NAFLD | generation of precursor metabolites and energy | 84/1882 | 490/18723 | 7.03e-07 | 3.95e-05 | 84 |
| GO:00066943 | Liver | NAFLD | steroid biosynthetic process | 34/1882 | 173/18723 | 1.01e-04 | 2.02e-03 | 34 |
| GO:00424452 | Liver | NAFLD | hormone metabolic process | 36/1882 | 218/18723 | 1.98e-03 | 1.98e-02 | 36 |
| GO:00421803 | Liver | NAFLD | cellular ketone metabolic process | 35/1882 | 211/18723 | 2.09e-03 | 2.06e-02 | 35 |
| GO:00229007 | Liver | NAFLD | electron transport chain | 29/1882 | 175/18723 | 4.87e-03 | 3.84e-02 | 29 |
| GO:000609112 | Liver | Cirrhotic | generation of precursor metabolites and energy | 238/4634 | 490/18723 | 6.85e-31 | 1.07e-27 | 238 |
| GO:002290012 | Liver | Cirrhotic | electron transport chain | 111/4634 | 175/18723 | 1.94e-27 | 1.52e-24 | 111 |
| GO:190136111 | Liver | Cirrhotic | organic cyclic compound catabolic process | 213/4634 | 495/18723 | 1.58e-19 | 3.67e-17 | 213 |
| GO:000820211 | Liver | Cirrhotic | steroid metabolic process | 143/4634 | 319/18723 | 2.79e-15 | 3.18e-13 | 143 |
| GO:004428211 | Liver | Cirrhotic | small molecule catabolic process | 151/4634 | 376/18723 | 2.20e-11 | 1.34e-09 | 151 |
| GO:00066941 | Liver | Cirrhotic | steroid biosynthetic process | 77/4634 | 173/18723 | 1.02e-08 | 3.91e-07 | 77 |
| GO:004218011 | Liver | Cirrhotic | cellular ketone metabolic process | 80/4634 | 211/18723 | 1.40e-05 | 1.95e-04 | 80 |
| GO:001604212 | Liver | Cirrhotic | lipid catabolic process | 112/4634 | 320/18723 | 2.31e-05 | 3.03e-04 | 112 |
| GO:004244511 | Liver | Cirrhotic | hormone metabolic process | 73/4634 | 218/18723 | 2.22e-03 | 1.36e-02 | 73 |
| GO:0008209 | Liver | Cirrhotic | androgen metabolic process | 15/4634 | 30/18723 | 2.45e-03 | 1.47e-02 | 15 |
| GO:000609122 | Liver | HCC | generation of precursor metabolites and energy | 340/7958 | 490/18723 | 4.04e-34 | 2.85e-31 | 340 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa01240 | Liver | Cirrhotic | Biosynthesis of cofactors | 66/2530 | 153/8465 | 3.11e-04 | 1.99e-03 | 1.23e-03 | 66 |
| hsa012401 | Liver | Cirrhotic | Biosynthesis of cofactors | 66/2530 | 153/8465 | 3.11e-04 | 1.99e-03 | 1.23e-03 | 66 |
| hsa012402 | Liver | HCC | Biosynthesis of cofactors | 103/4020 | 153/8465 | 4.67e-07 | 5.05e-06 | 2.81e-06 | 103 |
| hsa012403 | Liver | HCC | Biosynthesis of cofactors | 103/4020 | 153/8465 | 4.67e-07 | 5.05e-06 | 2.81e-06 | 103 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HSD17B6 | SNV | Missense_Mutation | c.244N>G | p.Leu82Val | p.L82V | O14756 | protein_coding | deleterious(0.01) | probably_damaging(0.913) | TCGA-D8-A1XL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide+tamoxifen | SD | |
| HSD17B6 | insertion | Nonsense_Mutation | novel | c.872_873insGACCAGCCTGGGCAACATAGTGAGACCTTGTGTCTACAAAAAATAAA | p.Phe291LeufsTer16 | p.F291Lfs*16 | O14756 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| HSD17B6 | SNV | Missense_Mutation | novel | c.4N>C | p.Trp2Arg | p.W2R | O14756 | protein_coding | deleterious(0) | benign(0.149) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| HSD17B6 | SNV | Missense_Mutation | novel | c.689N>T | p.Ala230Val | p.A230V | O14756 | protein_coding | tolerated(0.28) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| HSD17B6 | SNV | Missense_Mutation | novel | c.661N>A | p.Glu221Lys | p.E221K | O14756 | protein_coding | tolerated(0.66) | benign(0.001) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| HSD17B6 | SNV | Missense_Mutation | c.669N>C | p.Met223Ile | p.M223I | O14756 | protein_coding | tolerated(0.29) | benign(0) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
| HSD17B6 | SNV | Missense_Mutation | c.367N>C | p.Glu123Gln | p.E123Q | O14756 | protein_coding | deleterious(0.04) | possibly_damaging(0.808) | TCGA-AA-3502-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| HSD17B6 | SNV | Missense_Mutation | novel | c.778N>C | p.Asn260His | p.N260H | O14756 | protein_coding | deleterious(0.04) | benign(0.035) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| HSD17B6 | SNV | Missense_Mutation | novel | c.292N>G | p.Lys98Glu | p.K98E | O14756 | protein_coding | tolerated(0.06) | benign(0.068) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| HSD17B6 | SNV | Missense_Mutation | rs148211848 | c.199N>A | p.Glu67Lys | p.E67K | O14756 | protein_coding | tolerated(0.11) | benign(0.037) | TCGA-CM-6677-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |